ArticleJournal of medicinal chemistry2008
Antitumor compounds based on a natural product consensus pharmacophore.
Article in Journal of medicinal chemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Article
- Targeting RNA-binding proteins with small molecules: perspectives and challenges.Frontiers in chemistry · 2025Review
- Structure-Activity Relationship Study of Splicing Modulators on Hsh155/SF3B1 through Chemical Synthesis and Yeast Genetics.ACS medicinal chemistry letters · 2024Article
- Synthesis and Conformational Analysis of FR901464-Based RNA Splicing Modulators and Their Synergism in Drug-Resistant Cancers.Journal of medicinal chemistry · 2023Article
- Splicing modulators: on the way from nature to clinic.The Journal of antibiotics · 2021Review
- Total Syntheses of Pladienolide-Derived Spliceosome Modulators.Molecules (Basel, Switzerland) · 2021Review
- Structural basis of intron selection by U2 snRNP in the presence of covalent inhibitors.Nature communications · 2021Article
- New approaches to target RNA binding proteins.Current opinion in chemical biology · 2021Review
- Splicing modulator FR901464 is a potential agent for colorectal cancer in combination therapy.Oncotarget · 2019Article
- Alternative Splicing as a Target for Cancer Treatment.International journal of molecular sciences · 2018Review
- Molecular basis of differential 3' splice site sensitivity to anti-tumor drugs targeting U2 snRNP.Nature communications · 2017Article
- A Challenging Pie to Splice: Drugging the Spliceosome.Angewandte Chemie (International ed. in English) · 2017Review
- Review
- Modulating splicing with small molecular inhibitors of the spliceosome.Wiley interdisciplinary reviews. RNA · 2017Review
- A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore.Bioorganic & medicinal chemistry letters · 2017Article
- Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages.RNA (New York, N.Y.) · 2016Article
- Pharmacodynamic assays to facilitate preclinical and clinical development of pre-mRNA splicing modulatory drug candidates.Pharmacology research & perspectives · 2015Article
- Pre-mRNA splicing-modulatory pharmacophores: the total synthesis of herboxidiene, a pladienolide-herboxidiene hybrid analog and related derivatives.ACS chemical biology · 2014Article
- Asymmetric organocatalysis at the service of medicinal chemistry.ISRN organic chemistry · 2014Review
- Optimization of antitumor modulators of pre-mRNA splicing.Journal of medicinal chemistry · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
We report the design and highly enantioselective synthesis of a potent analogue of the spliceosome inhibitor FR901464, based on a non-natural product scaffold. The design of this compound was facilitated by a pharmacophore hypothesis that assumed key interaction types that are common to FR901464 and an otherwise unrelated natural product (pladienolide). The synthesis allows for the preparation of numerous novel analogues. We present results on the in vitro activity for this compound against several tumor cell lines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.